BR112022010425A2 - Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b - Google Patents

Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b

Info

Publication number
BR112022010425A2
BR112022010425A2 BR112022010425A BR112022010425A BR112022010425A2 BR 112022010425 A2 BR112022010425 A2 BR 112022010425A2 BR 112022010425 A BR112022010425 A BR 112022010425A BR 112022010425 A BR112022010425 A BR 112022010425A BR 112022010425 A2 BR112022010425 A2 BR 112022010425A2
Authority
BR
Brazil
Prior art keywords
interferon
binding proteins
treatment
hepatitis
infection
Prior art date
Application number
BR112022010425A
Other languages
English (en)
Portuguese (pt)
Inventor
Alam Antoine
Original Assignee
Evotec Int Gmbh
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh, Sanofi Sa filed Critical Evotec Int Gmbh
Publication of BR112022010425A2 publication Critical patent/BR112022010425A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022010425A 2019-12-03 2020-11-27 Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b BR112022010425A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306551 2019-12-03
EP19306572 2019-12-04
PCT/EP2020/083737 WO2021110561A1 (en) 2019-12-03 2020-11-27 Interferon-associated antigen binding proteins for use in treating hepatitis b infection

Publications (1)

Publication Number Publication Date
BR112022010425A2 true BR112022010425A2 (pt) 2022-08-23

Family

ID=73554457

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010425A BR112022010425A2 (pt) 2019-12-03 2020-11-27 Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b

Country Status (10)

Country Link
US (1) US20230028476A1 (enExample)
EP (1) EP4069290A1 (enExample)
JP (1) JP2023505169A (enExample)
KR (1) KR20220109435A (enExample)
CN (1) CN115052626A (enExample)
AU (1) AU2020397416A1 (enExample)
BR (1) BR112022010425A2 (enExample)
CA (1) CA3163356A1 (enExample)
IL (1) IL293449A (enExample)
WO (1) WO2021110561A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
EP4351732A1 (en) * 2021-06-09 2024-04-17 Evotec International GmbH Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2024126294A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126289A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024213635A1 (en) * 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
JP2013541937A (ja) * 2010-08-05 2013-11-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
ES2985566T3 (es) * 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
EP3439696A4 (en) * 2016-04-06 2019-12-25 University of Washington THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN
WO2018087345A1 (en) * 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
JP7676150B2 (ja) * 2018-06-01 2025-05-14 サノフイ Ｂ型肝炎ウイルス感染を治療するための併用療法

Also Published As

Publication number Publication date
AU2020397416A1 (en) 2022-07-14
KR20220109435A (ko) 2022-08-04
EP4069290A1 (en) 2022-10-12
CA3163356A1 (en) 2021-06-10
JP2023505169A (ja) 2023-02-08
WO2021110561A1 (en) 2021-06-10
IL293449A (en) 2022-07-01
US20230028476A1 (en) 2023-01-26
CN115052626A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
BR112022010425A2 (pt) Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
CO2021011295A2 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
BR112022010680A2 (pt) Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas
BR112022027038A2 (pt) Vacinas de replicon de rna contra hbv
BR112022011099A2 (pt) Tratamento de doenças relacionadas ao vírus da hepatite b
BR112022003698A2 (pt) Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica
ZA202001413B (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
MX2023005211A (es) Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden.
BR112022023135A2 (pt) Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
WO2021007070A3 (en) Chimeric antigens for treating viral infection
Liao et al. The Role of Interferon-Inducible Transmembrane Proteins in Virus Infection
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
MX2025002546A (es) Composición para el tratamiento de la infección por el virus de inmunodeficiencia humana.
BR112021021454A2 (pt) Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
BR112015020604A2 (pt) vírus da leucemia bovina (blv) atenuado recombinante, ácido nucleico, vetor, plasmídeo, célula hospedeira, composição farmacêutica, vacina, animal não humano, método de obtenção de material de animal não humano e material derivado de animal não humano
EA202191634A1 (ru) Замещенные арилметилмочевины и гетероарилметилмочевины, их аналоги и способы их применения